Close menu

December 20th, 2021 | 13:56 CET

Alibaba, Ayurcann, Rock Tech Lithium - Portfolio boosters for 2022

  • Cannabis
Photo credits:

The stock market year 2021 is slowly coming to an end, and many investors have cleaned up their portfolios. The question now is, which trends and stocks will ignite in the coming year! The Corona pandemic has come back into focus with the Omicron variant. So this vexed topic will continue to occupy us in the coming year. Profiteers from this are e-commerce companies like Alibaba. With the new traffic light government, the legalization of cannabis is being tackled. Efforts are increasing worldwide to make the consumption of hemp no longer a criminal offense. Well-positioned in this area is Ayurcann. An exciting third market is lithium, which is essential for the production of electric vehicles. Rock Tech Lithium is excellently positioned in this area.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    Alibaba - Turnaround in sight?

    Alibaba has not had a good year from a shareholder perspective. On the one hand, because of the regulation by the Chinese government, on the other hand, the annual forecast was cut, and the margins became smaller. When Didi announced its withdrawal from the New York Stock Exchange, the fear of delisting also went around among Alibaba shareholders. There are always accusations that the Company is not closely connected to social media, unlike WeChat and TikTok. Despite all the problems, what makes the stock a promising candidate for 2022?

    It has expanded its social media activities with DingTalk, reaching more than 500 million users. The Company is in a better economic position than all its competitors and already has competitive advantages in global e-commerce. If you look at the sales growth in combination with the margin, you quickly see that no one can keep up here. Amazon is growing less and has a 15% less margin. Pinduoduo and Bilibili are growing faster but making losses. Tencent has more margin but is growing 14% less. Due to greater competition within China, exponential growth has slowed.

    While e-commerce margins are declining, the profitability of other businesses is increasing significantly almost everywhere. The main opportunities are in the global market, and Alibaba, via AliExpress, knows how to connect international customers directly with Chinese manufacturers. In Eastern Europe in particular, they are well ahead of Amazon and are able to gain market share. It has also been able to gain market share in Western Europe, whereas its big competitor is stagnating. The specter of delisting should not worry investors too much. Alibaba ADR shares can be exchanged for corresponding shares in Hong Kong. That would likely weigh on the share price only in the short term.

    Ayurcann - Growing fast with high margins

    Canada-based Ayurcann Holdings Corp. offers licensed cannabis producers the opportunity to have their raw material refined post-harvest through the Company's offered outsourcing solutions. Services offered range from extraction and refining to bulk distillate oil sales, formulation and white-label manufacturing, fulfillment and distribution, and custom packaging solutions and inventory management services. Medical cannabis is also offered, such as tinctures, vapes for vaporizers, topicals, and creams. Canadian customers can purchase these products through the Ayurcann Marketplace, where they receive advice from expert staff.

    That cannabis is a growth market is shown by the annual figures. The fiscal year ended June 30, and sales increased by CAD 7 million or 1,149% over the previous year. Operating income was over CAD 2 million. An increase of 440%. On November 29, the Company released its third-quarter numbers and again, further growth can be seen. Revenues climbed 137% YOY to CAD 1.9 million. Profit was CAS 931,000, up 137%. The margin of 49% shows the attractiveness of the business. In addition, the expansion of production capacity at the Pickering Plant was completed. The Company can now process 300,000kg of biomass and expand filling up to 3 million packs.

    The Company has an international customer base that owns well-known cannabis brands - ranging from Xplor in the UK to Innocan Pharma from Israel to Green Bee Botanicals and Her Highness from the US. In the US, some states have legalized cannabis. The stock was previously listed on the CSE in Canada and Frankfurt. Since December 16, Americans have also been able to buy the shares on the OTCQB, the leading marketplace for startups in the US. Despite all the good news, the share is trading at just CAD 0.165, well below its high for the year at CAD 0.75. The market capitalization of CAD 20 million is significantly lower than that of the competitors and offers some catch-up potential.

    Rock Tech Lithium - The lithium market will continue to boom

    The hype around electric vehicles was one of the hot topics in 2021 and will remain so in the future. The switch from internal combustion engines to zero-emission drives creates a huge demand for lithium, cobalt and graphite needed to produce e-batteries. The Canadian Company Rock Tech Lithium wants to extract lithium from its mine in an environmentally friendly way and then convert it into lithium hydroxide using a converter. The first converter is to be built in Guben and start operation in 2024.

    One converter can supply around 500,000 electric cars with lithium hydroxide. Since the raw materials are finite, the Company has already looked into recycling the old e-batteries. That would cover the entire value chain and make the Company independent of lithium mining in the long term. As soon as the first lithium hydroxide factory is up and running, four more are to be built in Europe by 2029. As a result, according to management's plans, the Company is likely to capture about 30% of the European market.

    While the new plant is being prepared, pilot studies are underway to produce high-quality, battery-grade lithium hydroxide. The purity level must be more than 99.5%. In November, the trials were completed successfully. On December 3, the Company published the results of the technical study of the converter conducted by Wave International Pty. The plant will pay for itself within 64 months. Currently trading at CAD 6.02, the share has consolidated significantly after its recent rally and offers a first entry opportunity here at support.

    All three companies have significant upside potential. Unlike other e-commerce companies, Alibaba is trading near a multi-year low and is fundamentally cheap. Ayurcann is in the black, has good margins and is growing strongly. If you want to bet on cannabis, this is the place to be. Rock Tech Lithium offers attractive opportunities to enter the lithium market, which is set to become increasingly important in the coming years.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by Armin Schulz on September 20th, 2023 | 08:25 CEST

    Canopy Growth, Cantourage Group, Aurora Cannabis - Will the price fireworks come after legalization?

    • Cannabis

    For a long time, there was little reason for cannabis investors to rejoice. However, since Bloomberg reported that the US Department of Health and Human Services has asked the DEA to downgrade cannabis from Schedule 1 to Schedule 3, hopes for legalization are reviving. This downgrade would mean that cannabis would no longer be on par with heroin or other hard drugs. Democrats also want to give businesses in this sector legal access to bank accounts. In Germany, the traffic lights have approved Health Minister Lauterbach's plans to legalize cannabis. We, therefore, look at three companies that are betting on cannabis.


    Commented by Stefan Feulner on September 13th, 2023 | 09:55 CEST

    Cannabis stocks on a high - Aurora Cannabis, Viva Gold, Canopy Growth

    • Mining
    • Gold
    • Cannabis

    The exorbitant price jumps in the cannabis sector are reminiscent of the golden bull market days between 2015 and 2018. Back then, companies like Canopy Growth saw staggering increases of 5800%, and Aurora Cannabis soared over 6000%. After a years-long dry spell, various companies recently sent strong signs of life with a doubling of the share price within a few days. Additionally, the upward momentum promises to be sustainable as Aurora & Co. slowly move towards profitability.


    Commented by André Will-Laudien on September 11th, 2023 | 07:30 CEST

    The next steps towards cannabis THC legalization are underway! Canopy, Tilray and BioNTech are taking the lead, and Cantourage Group is experiencing dynamic growth

    • Cannabis
    • Biotechnology

    Cannabis has been decriminalized in some countries but legalized in only a few states. In the US, cannabis is fully legalized in states such as California but outright banned in others such as Texas. While medical use is slowly catching on, the use as an intoxicant and cultivation for personal use remains controversial. Stronger momentum could be sparked by the US Department of Health and Human Services (HHS). The authorities are open to a downgrading of the degree of danger in the categorization of the US Drug Enforcement Administration (DEA). We are talking about two steps from Schedule I to Schedule III, which no longer puts THC on a par with common drugs such as heroin, ecstasy or LSD but classifies them as substances with comparatively little psychological dependence. That would be a revolutionary step. Which stocks can benefit?